Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2016
At a glance
- Drugs Vorolanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Tyrogenex
- 08 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.
- 18 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 May 2014 Planned End Date changed from 1 Jun 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.